A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation

Mudge, David W., Tan, Ken-Soon, Miles, Rhianna, Johnson, David W., Badve, Sunil V., Campbell, Scott B., Isbel, Nicole M., van Eps, Carolyn L. and Hawley, Carmel M. (2012) A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation, 93 8: 822-826. doi:10.1097/TP.0b013e318248375a


Author Mudge, David W.
Tan, Ken-Soon
Miles, Rhianna
Johnson, David W.
Badve, Sunil V.
Campbell, Scott B.
Isbel, Nicole M.
van Eps, Carolyn L.
Hawley, Carmel M.
Title A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation
Journal name Transplantation   Check publisher's open access policy
ISSN 0041-1337
1534-6080
Publication date 2012-04
Sub-type Article (original research)
DOI 10.1097/TP.0b013e318248375a
Volume 93
Issue 8
Start page 822
End page 826
Total pages 5
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Collection year 2013
Language eng
Formatted abstract
BACKGROUND.
Anemia after kidney transplantation has been associated with poor transplant outcomes. We hypothesized that intravenous (IV) iron may more rapidly correct anemia than oral (PO) iron.

METHODS.

One hundred four kidney transplant recipients were prospectively randomized to IV iron polymaltose (500 mg single dose) or PO ferrous sulfate (210 mg elemental iron daily, continuously). The primary outcome was time to resolution of anemia, defined as hemoglobin more than or equal to 11 g/dL. Secondary outcomes included infections, blood transfusions, gastrointestinal side-effects, and acute rejection.

RESULTS.

There was no significant difference in the primary outcome comparing IV with PO iron (hazards ratio 1.22; 95% confidence interval 0.82-1.83; P=0.32). The median time to resolution of anemia was 12 days in the IV group versus 21 days in the PO group. There were no differences in infections (20% vs. 24%, P=0.62), acute rejection (8% vs. 6%, P=0.68), blood transfusions (10% vs. 18%, P=0.24), and severe gastrointestinal side-effects (6% vs. 12%, P=0.29) between the IV iron and the PO iron groups.

CONCLUSIONS.

We conclude that a single dose of IV iron did not result in more rapid resolution of anemia compared with PO iron. Both IV and PO iron are safe and effective in the management of posttransplant anemia.
Keyword Anemia
Iron
Kidney transplantation
Mycophenolate-Mofetil Absorption
Renal-Transplantation
Recipients
Deficiency
Prevalence
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 May 2012, 21:03:09 EST by System User on behalf of Medicine - Princess Alexandra Hospital